Clinical and microbiological characteristics of reactive infectious mucocutaneous eruption: A case series of 5 patients
Abstract
EBV: Epstein-Barr virus IgM: immunoglobulin M PCR: polymerase chain reaction RIME: reactive infectious mucocutaneous eruption INTRODUCTION The clinical syndrome characterized by an acute mucositis, with variable involvement of the oral, ocular, and genital mucosa and minimal or absent skin involvement, has been described as ‘‘atypical Stevens-Johnson syndrome,’’ ‘‘Stevens-Johnson syndrome without skin lesions,’’ and ‘‘Fuchs syndrome.’’ In the past few years, a new nomenclature was introduced, mostly focused on the etiologic agent, Mycoplasma pneumoniae, including terms such as ‘‘Mycoplasma pneumoniaeeassociated mucositis’’ and ‘‘Mycoplasma-induced rash and mucositis’’; more recently, the concept of reactive infectious mucocutaneous eruption (RIME) has been proposed to act as an umbrella term including all mucosa-predominant acute parainfectious eruptions. The histopathologic findings of this condition are similar to those found in the Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum, with apoptotic keratinocytes up to a full-thickness epidermal necrosis with subepidermal split, and a sparse superficial inflammatory infiltrate. Here, we present the clinical records of 5 patients with features of RIME to highlight the key features of this condition that we believe could be helpful in the diagnosis and treatment of this condition in daily practice.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.